scarring

Promore's phase 2 scar trial fail sends stock spiraling down

The nine-year wait for new clinical data ended in disaster, with the failure of the polypeptide to reduce scarring wounding the biotech’s share price.

Nick Paul Taylor Apr 20, 2023 7:15am

Acelyrin snags $250M, licenses Affibody IL-17 asset for 3 trials

Nov 16, 2021 5:00am

'Safety concerns' see Biogen ax phase 2 study of fibrosis med

Sep 17, 2019 2:56am

AzurRx’s chronic pancreatitis drug hits the mark in phase 2

Sep 24, 2018 4:53pm

Early trial shows application of RXi’s skin-scar drug in wet AMD

Aug 1, 2018 2:42pm

Regenerating hair follicles could be key in reducing scar tissue

Jan 5, 2017 2:01pm